There are currently 324 active clinical trials seeking participants for Obesity research studies. The states with the highest number of trials for Obesity participants are California, Texas, Florida and North Carolina.
A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597
Recruiting
This is a Phase 2, single-center, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 26 weeks.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
07/01/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Prader-Willi Syndrome, Obesity, Hyperphagia
Register for Updates
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
NCT06804603
Recruiting
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2025
Locations: Vanda Investigational Site, Los Angeles, California +2 locations
Conditions: Obesity
Register for Updates
Acute Exercise on Brain Insulin Sensitivity
NCT05853913
Recruiting
Dementia is a leading cause of death in the United States among aging adults. Brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise decreases Alzheimer's Disease (AD) risk, in part, through changes in brain structure and function. However, there is limited data available on how exercise impacts brain insulin resistance in aging. This study will test the effect of acute exercise on brain insul... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
06/30/2025
Locations: Institute for Food, Nutrition, and Health, New Brunswick, New Jersey +3 locations
Conditions: Aging, Obesity, Insulin Resistance, Cognition, Cardiovascular Disease Risk
Register for Updates
Extracellular Vesicles, Insulin Action, and Exercise
NCT06546085
Recruiting
Extracellular vesicles (EVs) play a role in obesity-induced insulin resistance and likely impact the development of cardiovascular disease. However, little is known on how EVs affect vascular insulin action in people. The purpose of this study is to understand how EVs play a role in type 2 diabetes related cardiovascular disease. This research will also study if exercise can change how EVs impact blood flow and metabolic health. This study will contribute to designing precision medicine to treat... Read More
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
06/30/2025
Locations: Institute for Food, Nutrition, and Health, New Brunswick, New Jersey +2 locations
Conditions: Type 2 Diabetes, Obesity
Register for Updates
New Heart Imaging Techniques to Evaluate Possible Heart Disease
NCT01399385
Recruiting
Background: - Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see the amount of blood vessel narrowing and vessel wall thickness. This information may help diagnose and treat heart disease and other conditions that lead to heart attacks. Better MRI methods are needed to improve heart disease diagnosis, especially by avoiding the use of radiation. Researchers are testing new techniques to improve the qualit... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Healthy, Obesity, Diabetes, Healthy Volunteers, Atherosclerosis
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Valley Clinical Trials, Covina, California +36 locations
Conditions: Obesity
Register for Updates
Pharmacogenetics of Response to GLP1R Agonists
NCT05071898
Recruiting
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA. Pharmacodynamic responses to GLP1R agonist will be assessed by conducting frequently sampled intravenous glucose tolerance tests (FSIGT) both before and after semaglutide for six weeks. The proposal proposes two specific aims: 1. Specific Aim #1. To identify genetic variants associated with effects of a GLP1R agonist to enhance glucose-stimulated fir... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/26/2025
Locations: Amish Research Clinic, Lancaster, Pennsylvania
Conditions: Obesity, Diabetes Type 2
Register for Updates
Role of Aging and Individual Variation in Exercise Training Responsiveness
NCT06471569
Recruiting
The primary purpose of this study is to assess the effects of aging on markers of physical reserve and exercise-induced adaptations in resilience in older adults who completed a structured exercise program within the last 15 years (Parent trial: STRRIDE-PD; NCT00962962). This feasibility pilot study will enroll up to 8 participants to complete a 6-month aerobic exercise intervention.
Gender:
ALL
Ages:
Between 60 years and 90 years
Trial Updated:
06/26/2025
Locations: Duke Center for Living, Durham, North Carolina
Conditions: Prediabetic State, Cardiovascular Diseases, Insulin Resistance, Obesity
Register for Updates
Exercise Effects on Adipose Tissue Structure and Function
NCT04812314
Recruiting
Participants will be randomized into one of two different experimental groups: 1) Exercise group and 2) No exercise (control group). Subject participation in the study will involve a series of metabolic tests before and after participants undergo a 10% weight loss program (with or without exercise training depending on group randomization). After completing this weight loss portion of the study, participants will then be required to adhere to a high calorie diet program to regain half of the wei... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
06/25/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Obesity, Metabolic Syndrome, Metabolic Disease, Insulin Resistance, Weight Loss, Weight Gain
Register for Updates
Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation
NCT05880108
Recruiting
The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.
Gender:
ALL
Ages:
80 years and below
Trial Updated:
06/25/2025
Locations: Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD, Baltimore, Maryland +1 locations
Conditions: Post-COVID Conditions, Obesity
Register for Updates
SMARTer Weight Loss Management
NCT05861973
Recruiting
The SMARTer trial will be a three-arm, randomized controlled non-inferiority trial that compares the optimized, adaptive SMARTer intervention, fixed DPP, and Self-Guided (Control). The trial will address whether a scalable, stepped-care intervention can stand up to gold-standard DPP by achieving comparable weight loss at a lower cost. Alongside evaluation of clinical non-inferiority, a comprehensive economic evaluation will inform relative affordability. Cost information is important to inform t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Obesity
Register for Updates
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792
Recruiting
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona +88 locations
Conditions: Obesity, Overweight, Type 2 Diabetes
Register for Updates